Cargando…

Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022

BACKGROUND: We aimed to estimate vaccine effectiveness against infection (VE-infection) and against further transmission (VE-infectiousness) in a household setting during Delta and Omicron. Knowing these effects can aid policy makers in deciding which groups to prioritize for vaccination. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoeve, Christina E, de Gier, Brechje, Huiberts, Anne J, de Melker, Hester E, Hahné, Susan J M, van den Hof, Susan, Knol, Mirjam J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428192/ https://www.ncbi.nlm.nih.gov/pubmed/37093964 http://dx.doi.org/10.1093/infdis/jiad110

Ejemplares similares

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
por: Huiberts, Anne J, et al.
Publicado: (2023)

Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
por: Huiberts, Anne J., et al.
Publicado: (2023)

Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
por: de Gier, Brechje, et al.
Publicado: (2023)

Out-of-season increase of puerperal fever with group A Streptococcus infection: a case–control study, Netherlands, July to August 2018
por: van den Boogaard, Jossy, et al.
Publicado: (2020)

Higher risk of SARS-CoV-2 Omicron BA.4/5 infection than of BA.2 infection after previous BA.1 infection, the Netherlands, 2 May to 24 July 2022
por: Andeweg, Stijn P, et al.
Publicado: (2023)

COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021
por: van Ewijk, Catharina E, et al.
Publicado: (2022)

Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022
por: van Iersel, Senna C.J.L., et al.
Publicado: (2023)

Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
por: Andeweg, Stijn P., et al.
Publicado: (2022)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Knol, Mirjam J, et al.
Publicado: (2022)

Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021–January 2022
por: de Gier, Brechje, et al.
Publicado: (2023)

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
por: Ohm, Milou, et al.
Publicado: (2021)

The dynamics of scarlet fever in The Netherlands, 1906–1920: a historical analysis
por: McDonald, Scott A., et al.
Publicado: (2022)

Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021
por: de Gier, Brechje, et al.
Publicado: (2021)

Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6–14 Months During a Measles Outbreak in The Netherlands in 2013–2014
por: van der Maas, Nicoline A. T., et al.
Publicado: (2016)

Measles Outbreak, the Netherlands, 2008
por: Hahné, Susan, et al.
Publicado: (2010)

Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021
por: de Gier, Brechje, et al.
Publicado: (2021)

Epidemic of Mumps among Vaccinated Persons, the Netherlands, 2009–2012
por: Sane, Jussi, et al.
Publicado: (2014)

Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands
por: van Lier, Alies, et al.
Publicado: (2019)

Disease burden of neonatal invasive Group B Streptococcus infection in the Netherlands
por: de Gier, Brechje, et al.
Publicado: (2019)

Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis
por: Nic Lochlainn, Laura M, et al.
Publicado: (2019)

Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022
por: Eggink, Dirk, et al.
Publicado: (2022)

Increase in invasive disease caused by Haemophilus influenzae b, the Netherlands, 2020 to 2021
por: Steens, Anneke, et al.
Publicado: (2021)

Occupation- and age-associated risk of SARS-CoV-2 test positivity, the Netherlands, June to October 2020
por: de Gier, Brechje, et al.
Publicado: (2020)

Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004–2016
por: Brandwagt, Diederik A. H., et al.
Publicado: (2019)

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018
por: Knol, Mirjam J, et al.
Publicado: (2018)

Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands
por: Tielemans, Susanne M A J, et al.
Publicado: (2017)

Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis
por: Nic Lochlainn, Laura M, et al.
Publicado: (2019)

Neighbourhood sociodemographic factors and COVID-19 vaccine uptake in the Netherlands: an ecological analysis
por: Labuschagne, Lisanne J. E., et al.
Publicado: (2023)

The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015–2018
por: Loenenbach, Anna D, et al.
Publicado: (2020)

Economic Costs of Measles Outbreak in the Netherlands, 2013–2014
por: Suijkerbuijk, Anita W.M., et al.
Publicado: (2015)

Participation in and attitude towards the national immunization program in the Netherlands: data from population-based questionnaires
por: Mollema, Liesbeth, et al.
Publicado: (2012)

Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015
por: Wagenvoort, Gertjan H J, et al.
Publicado: (2017)

Large measles epidemic in the Netherlands, May 2013 to March 2014: changing epidemiology
por: Woudenberg, Tom, et al.
Publicado: (2017)

Determinants of COVID-19 Vaccine Uptake in The Netherlands: A Nationwide Registry-Based Study
por: Pijpers, Joyce, et al.
Publicado: (2023)

Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands
por: Thorrington, Dominic, et al.
Publicado: (2018)

The use of tetanus post-exposure prophylaxis guidelines by general practitioners and emergency departments in the Netherlands: a cross-sectional questionnaire study
por: Donken, Robine, et al.
Publicado: (2014)

Pathogen- and Type-Specific Changes in Invasive Bacterial Disease Epidemiology during the First Year of the COVID-19 Pandemic in The Netherlands
por: Steens, Anneke, et al.
Publicado: (2022)

Kinetics of SARS-CoV-2 Serum Antibodies Through the Alpha, Delta, and Omicron Surges Among Vaccinated Health Care Workers at a Boston Hospital
por: Dodge, Maura C, et al.
Publicado: (2023)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: Knol, Mirjam J., et al.
Publicado: (2015)

Mumps Serum Antibody Levels Before and After an Outbreak to Assess Infection and Immunity in Vaccinated Students
por: Gouma, Sigrid, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cl68adgq31b8065nsfip9b5ugu